Mark Corriere, MD
Internal Medicine · Columbia, MDNPI 1053350843
Payments from drug & device makers
Across 617 payments — averaging $651.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$173K
- Sanofi-aventis U.S. LLC$74K
- Ascensia Diabetes Care US Inc.$44K
- Lilly USA, LLC$35K
- Bayer$28K
- AstraZeneca$27K
- plus $21K from 28 others
What the payments were for
- Consulting fees$34,9609%
- Speaking & faculty fees$343,14785%
- Travel & lodging$12,8753%
- Food & beverage$10,8293%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 227 | $172,650 |
| Sanofi-aventis U.S. LLC | 111 | $73,650 |
| Ascensia Diabetes Care US Inc. | 26 | $43,970 |
| Lilly USA, LLC | 84 | $35,334 |
| Bayer | 30 | $28,098 |
| AstraZeneca(2 entities) | 41 | $27,094 |
| AbbVie | 33 | $12,363 |
| Senseonics, Incorporated | 4 | $4,645 |
| Zealand Pharma US, Inc. | 6 | $3,009 |
| GSK | 1 | $124 |
| Dexcom, Inc. | 5 | $103 |
| Inspire Medical Systems, Inc. | 1 | $101 |
| Amgen(2 entities) | 5 | $97 |
| Novartis | 3 | $78 |
| Abbott | 3 | $74 |
| Amneal Pharmaceuticals LLC | 4 | $69 |
| Xeris Pharmaceuticals, Inc. | 4 | $68 |
| Medtronic | 3 | $56 |
| BETA Bionics, Inc. | 4 | $49 |
| Johnson & Johnson | 3 | $45 |
| Corcept Therapeutics | 2 | $45 |
| Radius Health, Inc. | 2 | $42 |
| Cequr Corporation | 2 | $37 |
| Boehringer Ingelheim | 2 | $34 |
| Sequel Med Tech, LLC | 1 | $24 |
| IBSA Pharma Inc. | 1 | $22 |
| GRT US Holding, Inc. | 1 | $19 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $14 |
| Lifescan, Inc. | 1 | $14 |
| Companion Medical, Inc. | 2 | $11 |
| Mannkind Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$97,246
- Ozempic$69,341
- SOLIQUA 100/33$47,028
- FARXIGA$26,561
- Kerendia$26,394
- TOUJEO$22,831
- LYUMJEV$20,000
- EVERSENSE E3 SENSOR KIT - RETAIL$12,021
- Synthroid$10,720
- EVERSENSE E3 SMART TRANSMITTER KIT$8,000
- HUMULIN$7,400
- Eversense$4,645
- ZEGALOGUE$2,880
- EVERSENSE 365 SENSOR KIT (RETAIL)$2,763
- DISEASE STATE$2,420
- Non-Covered$1,364
- TRULICITY$322
- TZIELD$163
- AREXVY$124
- UBRELVY$120
How this compares
$402,004 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 220 | $437,460 |
| MounjaroTirzepatide | 121 | $190,362 |
| TrulicityDulaglutide | 106 | $171,959 |
| JardianceEmpagliflozin | 110 | $168,511 |
| FarxigaDapagliflozin Propanediol | 63 | $89,016 |
| Tresiba Flextouch U-200Insulin Degludec | 49 | $72,022 |
| RybelsusSemaglutide | 32 | $71,274 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 36 | $52,364 |
| JanuviaSitagliptin Phosphate | 46 | $45,837 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 62 | $45,813 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 26 | $43,544 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $40,189 |
| Tresiba Flextouch U-100Insulin Degludec | 61 | $40,146 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $33,040 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 22 | $29,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $172,650 | $524,121276 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $35,334 | $366,807249 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $34 | $218,763150 claims |
| AstraZenecaFarxiga | $27,094 | $89,01663 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $73,650 | $43,54426 claims |
| AmgenProlia | $97 | $22,95113 claims |
| AbbVieSynthroid | $12,363 | $7,97193 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $69 | $3,240303 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Columbia
- Saba SheikhColumbia$342K
- William SawayColumbia$295K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.